One-Stop mRNA CAR-T Therapy Development

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Chimeric Antigen Receptor (CAR) T-cell therapy is a groundbreaking immunotherapy that has demonstrated remarkable success in the treatment of hematological malignancies. Traditionally, CAR-T therapies utilized viral vectors for gene delivery, raising concerns about safety and manufacturing challenges. In contrast, mRNA CAR-T therapy employs a non-viral approach, capitalizing on the transient expression of CAR molecules in T-cells.

Figure 1. The scheme of IVT mRNA CAR T therapy in cancer patients.¹

Our mRNA CAR-T therapy leverages the simplicity and safety of mRNA, offering several pivotal advantages that distinguish it from traditional approaches.

IVT mRNA Vector Products

To comprehend mRNA CAR-T therapy, it is essential to understand the core component – in vitro transcribed (IVT) mRNA. IVT mRNA is a synthetic version of natural mRNA, engineered to express the desired CAR constructs. Creative Biolabs specializes in the design and production of high-quality IVT mRNA vectors tailored to your specific target antigen.

Our team of experts is equipped with the expertise to design and optimize the IVT mRNA vector, ensuring maximal CAR expression, minimized off-target effects, and enhanced translational efficiency. These vectors can be readily modified to target different antigens, demonstrating the versatility of mRNA CAR-T technology.

CAR mRNA LNPs Products

One of the key challenges in mRNA-based therapy is the efficient delivery of mRNA to target cells. Creative Biolabs addresses this challenge with the utilization of Lipid Nanoparticles (LNPs). LNPs are lipid-based carriers that protect the fragile mRNA cargo, enhance cellular uptake, and facilitate endosomal escape, thus ensuring optimal translation of the CAR protein.

Our proprietary LNP formulations have been meticulously developed to achieve high delivery efficiency while minimizing cytotoxicity. This expertise empowers us to offer a streamlined and highly effective mRNA CAR-T therapy development service.

One-Stop mRNA CAR-T Therapy Development Service Workflow

Creative Biolabs' One-Stop mRNA CAR-T Therapy Development service encompasses a streamlined, efficient, and end-to-end workflow that facilitates the development of customized mRNA CAR-T therapies.

Target Antigen Selection: Our experts collaborate with you to identify the most suitable target antigens for your specific application.
IVT mRNA Vector Design: We design and optimize IVT mRNA vectors encoding the CAR construct tailored to the chosen antigen.
LNP Formulation: Our advanced LNP formulations ensure efficient delivery of the mRNA to T-cells.
Cell Isolation and Transfection: We isolate patient T-cells and transfect them with the customized mRNA CAR constructs, creating patient-specific CAR-T cells.
In Vitro Validation: Rigorous in vitro testing ensures CAR expression, cytotoxicity, and functionality.
Preclinical Evaluation: Preclinical studies assess the efficacy and safety of the developed mRNA CAR-T therapy.

mRNA CAR Advantages

The advantages of mRNA CAR-T therapy over traditional viral vector-based CAR-T therapies are significant. These advantages include:

Enhanced Safety: Since mRNA is a transient molecule, it poses minimal risk of genomic integration or off-target effects, improving safety profiles.
Rapid Development: mRNA CAR constructs can be rapidly designed and synthesized, allowing for quicker adaptation to evolving cancer targets.
Reduced Manufacturing Complexity: Eliminating the need for viral vector production simplifies manufacturing and reduces associated costs.
Patient-Specific Therapy: mRNA CAR-T therapies can be customized for individual patients, optimizing treatment outcomes.
Reduced Immunogenicity: mRNA-based therapies are less likely to trigger immune responses, improving tolerability.

In conclusion, mRNA CAR-T therapy represents a revolutionary leap forward in the field of immunotherapy. Its safety, flexibility, and rapid development potential make it a promising avenue for cancer treatment. Creative Biolabs is committed to advancing the field through our expertise and the One-Stop mRNA CAR-T Therapy Development service. Together, we are shaping the future of cancer therapy.

For more information on our service and to explore how we can collaborate on your next project, please get in touch with our expert team.

Reference

Soundara Rajan, Thangavelu, et al. "In vitro-transcribed mRNA chimeric antigen receptor T cell (IVT mRNA CAR T) therapy in hematologic and solid tumor management: a preclinical update." International journal of molecular sciences 21.18 (2020): 6514.